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estimate costs for in-and outpatients. RESULTS: Among the 264_PAND and
132_POST inpatients, 30% were 18 years old, and 45% were women. The mean
length of stay at general ward was of 6.5(6.1)-7.0(6.6) days (PAND and POST, respec-
tively); and between 8.2(5.0) and 11.5(15.2) days for ICU patients (7%_PAND and
20%_POST). Among employed (45.3% PAND and 37.7% POST) most went on sick
leave (99% and 93%) for about 31(37) and 38(27) days. Among outpatients
(215_PAND and 175_POST), about 25-35% were under 17 years old, and 50-57% were
women. The 94%(PAND) and 82%(POST) of employed (64,9% and 68,0%, respec-
tively) went on sick leave. Absenteeism length of was 11(12)-7(45) days. The mean
cost per inpatient was 6,028 € (SD6,251) in PAND and 6,939€(SD10,895) in POST.
For outpatients the mean cost was 749€ (SD886) in PAND and 421€ (SD686) in
POST. CONCLUSIONS: Contrary to what expected, resource utilization was quite
similar for both influenza waves. However, differences on mean cost were found
due to the slightly increase in inpatients health care utilization, and the decrease of
absenteeism among outpatients during the post-pandemic wave. These results
would be useful to assess the influenza real burden in Spain; both at individual and
population level.
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OBJECTIVES: To estimate direct medical costs of atopic dermatitis (AD) from a US
payer perspective. METHODS: Data came from a large employer-based longitudi-
nal claims database, which captures person-specific clinical utilization, expendi-
tures, and enrollment across inpatient, outpatient, prescription drug, and carve-
out services. A matched case-control study design was employed. Cases were
identified based on at least two AD-related medical claims with an International
Classification of Disease v9 codes of 691.8x or 692.x anytime during the calendar
year of 2009. Three controls were matched to each case based on age, gender, type
of health plan enrolled, and censes region. Multivariate robust regression models
were used to estimate the incremental burden of AD. A non-parametric bootstrap
technique with 1000 replications was used to estimate the distribution of the beta
coefficients and derive the 95% confidence limits. RESULTS:A total of 119,252 cases
were matched to 357,756 controls with an average age of 46 years (SD23.9), and
57% females. AD-related comorbidities such as allergic rhinitis, asthma, other
types of allergies, sleep disturbances and attention deficit disorders were signifi-
cantly greater (p0.01) in proportion among cases vs. controls. After adjusting for
all baseline differences, cases on an average had $912 (95% CL:$781-$1,042) greater
overall cost per subject compared to controls. Top three drivers were attributed to
outpatient costs (58%, $533), inpatient costs (22%, $201), and pharmacy costs (15%,
$139), respectively. Among cases, dermatology-related overall costs were 370%
(from $127 to $470) greater post index event. Over 80% of this increase was attrib-
utable to dermatology-related outpatient costs. Approximately, three additional
dermatology-related outpatient visits were observed in the follow-up period com-
pared to baseline. CONCLUSIONS: AD is costing the U.S. payer an additional $912
per-patient-per-year compared to subjects with no AD. Future research should
determine the impact of current treatment on the economic burden of this disease.
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OBJECTIVES: The economic burden of heart failure (HF) has increased rapidly with
the increasing prevalence and incidence of HF patients all around the world. In this
abstract, the cost analysis of hospitalized HF patients is presented. METHODS: A
sample of hospitalizations (n166, year 2011) with diagnoses related with chronic
HF in a state hospital serving to a wide range of populations was evaluated. The
prices for ICU stay and cardiovascular procedures paid by Turkish state health
security system were applied. Indirect costs are not taken into account. RESULTS:
Twelve percent of the stays were in intensive care unit (ICU), 35% were in medical
ward only and 53% of the stays were partly in ICU and medical ward; average
duration were 2.513.09 days, 4.454.07 days and 6.955.08 days, respectively. ICU
stays are paid with fixed prices, without allowance for any extra payment for
services or procedures performed while the patient stays in ICU. Average daily and
total costs of ICU stay are calculated as 402€/day and 1006€, respectively. On the
other hand, procedures are paid per service, while the patient stays in medical
ward. Therefore the fixed amounts of payments for cardiovascular procedures,
which are mostly performed during the stay of HF patients, were averaged by the
frequencies of individual procedures. This yielded to 531€ per stay. Therefore the
total cost of stay was obtained as 1537€, and average daily cost of stay as 221€/day.
CONCLUSIONS: These figures are quite concordant with a previous analysis re-
ported in 2009 (total cost of stay 1617€ and daily cost of stay 245€/day) in which
micro-costing methods had been applied. Therefore these figures presented in this
report could be used local input parameters for health economics models for HF.
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OBJECTIVES: Inappropriate shocks are the most common complications of ICD,
causing a negative effect on patients’ morbidity and mortality. Little is known with
regards to the cost associated to the management of IS. The aim of the study was to
determine IS related factors and to evaluate its associated hospital cost.METHODS:
All patients implanted with an ICD where retrospectively analyzed through clinical
chart reviews in a Spanish hospital from 2003 to 2011. Demographic variables,
baseline cardiomyopathy, comorbidities, indication and type of ICD implanted
were registered. During the follow up period we identified the presence of IS, its
reasons and associated costs. RESULTS: A total of 227 patients were implanted
with an ICD, mean age 63.2 years (26-82). Eighty-six percent were men, 64.6% with
ischemic cardiomyopathy, 78.4% with heart failure, 70.4% with EF35% and 13.1%
with AF. The proportion of single, dual and three chambers ICD was 54.6%, 20.3%
and 25.1% respectively. After a median follow up of 4.46 years, 27 patients had had
42 IS episodes. Average time since implant to first IS was 1.3 years (range 0.02 to 3.84
years). Patients suffering from IS had higher mortality (33.3% vs 13.7%; p0.05).
Amost 67% of the episodes were due to supraventricular tachycardia, 12% to noise
detection, 19% to Wave T overdetection and 2.3% due to other causes. Sixty-three
percentages of the episodes generated an emergency visit and a 39% generated a
non-scheduled visit to the cardiologist. Seven episodes (16.7%) required hospital-
ization, six of whom required a surgical intervention. Average length of stay was
5.1 days. Finally, overall mean hospital cost appeared to be €5,175 per episode.
CONCLUSIONS: The cost of inappropriate shocks is driven by the reason of its
cause. The great majorities of the episodes were due to supraventricular arrhyth-
mias and finally resolved without the need for hospitalization.
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OBJECTIVES: To assess out-of-pocket expenses reported by patients receiving
chronic treatment for atrial fibrillation (AF) in five European countries. METHODS:
The EUPS-AF questionnaire was adapted from the 2008 Commonwealth Fund In-
ternational Health Policy Survey of Chronically Ill Adults. Computer-assisted digi-
tal telephone dialling was used to screen a random sample from the entire adult
populations of France, Germany, Italy, Spain and the UK. Structured telephone
interviews were conducted between February and July 2011. RESULTS: Interviews
were conducted with 1507 patients (France, n300; Germany, n300; Italy, n302;
Spain, n305; UK, n300). On average, 40% of patients had incurred no out-of-
pocket expenses for medical treatment or services over the past 12 months (range,
18% [Italy] to 75% [UK]). Of the 582 patients who reported out-of-pocket expenses
(mean, €705), 221 (44%) declared that the costs included those due to AF (mean,
€466). The lowest mean out-of-pocket cost per patient for AF care was reported in
France (€92 [median, €82], n14) and the highest in the UK (€1573 [median, €114],
n29). The majority of out-of-pocket expenses for AF were non-medical costs for
treatment and services not covered by insurance, including travel and household
help. The proportion of patients who claimed cost as a reason for not filling a
prescription or skipping doses ranged from 3% in the UK and Spain to 10% in
France. Failure to receive treatment due to lack of reimbursement was experienced
least frequently in the UK (1% of patients) and most frequently in Germany (28% of
patients). CONCLUSIONS: The EUPS-AF highlights differences in out-of-pocket ex-
penses and levels of treatment reimbursement that patients with AF have to pay in
five European countries. Payers, health care policy makers and clinicians should all
be aware that the financial burden of AF is linked to treatment adherence and may
affect patient satisfaction and treatment outcome.
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OBJECTIVES: Streptococcus pneumoniae causes a wide spectrum of illness from
upper respiratory tract infection to severe invasive pneumococcal disease (IPD),
defined as the identification of S. pneumoniaea normally sterile site. The most
severe IPD forms are meningitis, bacteraemia and septicaemia. Older adults are in
an increased risk of death from IPD. The former socialistic countries of the central
Europe form a unique region with specific health care and epidemiology charac-
teristics, and where the local evidence on the underlying epidemiology is scarce.
The objective was to estimate the economic burden of IPD in those50 years of age
in the Czech Republic (CR), Slovakia (SK), Poland (PL), and Hungary (HU) using most
recent data available. METHODS: The incidence of IPD stratified by age groups
50-64, 65-74, 75-84 and 85 was obtained from national surveillance systems (PL,
A521V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
